Acromegaly Market Size was USD 1326.6 million in 2021 and it is expected to rise during the study period (2019-2032) – Digital Journal

The Acromegaly Market is expected to show positive growth in the forecast period (20222032) due to the development of well-designed, randomized, controlled non-crossover trials with potential benefits. Moreover, the shortfall of approved therapy might provide suitable space for emerging therapies.

The Global Protein Therapeutics Market size is expected to reach $490.2 billion by 2028, rising at a market growth of 6.9% CAGR during the forecast…

ReportLinker Protein therapeutic medicines are a class of pharmaceuticals used to treat a range of illnesses, including cancer, metabolic, hematological, immunological, hormonal, genetic, contagious diseases, and others. New York, Sept

Patents to biological medicines in combination: is two really better than one? – Lexology

New medicines are usually protected by a patent covering the active molecule. These basic or primary patents usually provide robust protection for the relevant product, provided that the compound is genuinely new and inventive. Developers may be able to extend patent protection by patenting other technological advances related to the drug such as new formulations, dosage forms or regimens, and new combinations with other pharmaceuticals

The Leg Press Vs. the Squat Who Wins the Battle for Leg Day? – BarBend

When youre serious about growing lower body strength, power, and muscle, you cannot go past the barbell squat and the leg press. These lifts are often the top two contenders in strength programs when it comes to lower body muscle and strength. But given a choice, should you do the leg press or the squat?

Growth hormone in IVF: the endometrial effect – ESHRE

A new meta-analysis finds that treatment with growth hormone in IVF is associated with improved reproductive outcomes largely mediated by an effect on endometrial function, especially in poor responders. A multitude of studies have already examined the role of GH in its effect on oocyte quality, and thereby success rates, but without clear conclusions. A Cochrane review from 2021 described the result of adjuvant GH in normal IVF responders as very uncertain, both in terms of LBR and gonadotrophin dose.(2) The effect on LBR was similarly uncertain in poor responders, although the Cochrane reviewers did report a slight increase in the number of oocytes retrieved and in pregnancy rate